The first day of new shares | Dingdang Health opened 2.83% higher, with a pre-market turnover of HK$14.2651 million-clevelanddrifters.com

current location：Home > Stock market > The first day of new shares | Dingdang Health opened 2.83% higher, with a pre-market turnover of HK$14.2651 million text

The first day of new shares | Dingdang Health opened 2.83% higher, with a pre-market turnover of HK$14.2651 million

time：2023-03-24 00:27:45 source：clevelanddrifters.com author：Garbage

The first day of new shares | Dingdang Health opened 2.83% higher, with a pre-market turnover of HK$14.2651 million

According to news from Futu Information on September 14, $Dingdang Health (09886.HK)$ opened 2.83% higher on the first day at HK$12.34, and the pre-market turnover reached HK$14.2651 million. In yesterday's Futu dark market trading, Dingdang Health opened 5% higher, and finally closed up 5.5%, earning HK$330 per lot. According to the previous public information, Dingdang Health had 6,502 people who subscribed for public placement, the first-hand lottery rate was 11.22%, and the first-hand subscription was stable for 10 lots. The relevant data compiled by Futu Information are as follows: Dingdang Health, as a service provider providing digital medical health home services in China, since its establishment in 2014, has been pioneering online-to-offline solutions for real-time drug retail and medical consultation (including The operation of online platforms, offline smart pharmacies and fast medicine services) has prompted the transformation and upgrading of China's medical industry. According to the Frost & Sullivan Report, Dingdang Health is a leading service provider in China's digital retail pharmacy industry in terms of revenue in 2021, ranking third in the industry with a market share of 1.0%. According to the Frost & Sullivan Report, the Company is the largest product and service provider in the instant home digital pharmacy industry in China in terms of revenue in 2021, with a market share of 6.8%. Dingdang Health has connected industry participants including medical personnel, pharmacies, pharmaceutical companies and other stakeholders in the entire value chain to build a closed-loop ecosystem featuring a combination of medical and health products and services, driven by technology, and centered on users system. The company utilizes comprehensive online and offline operations to provide users with a full range of medical and health home products and services, such as fast medicines, online diagnosis and treatment, and chronic disease and health management. In terms of finance, from 2018 to 2021, the company's total revenue was 580 million yuan, 1.28 billion yuan, 2.23 billion yuan, and 3.68 billion yuan, with a compound annual growth rate of 84.62%. In the first three months of 2021 and 2022, the company's total revenue is 780 million yuan and 990 million yuan, respectively, with a year-on-year growth rate of 26.64%. Risk warning: The opinions of the authors or guests shown above have their own specific positions, and investment decisions need to be based on independent thinking. Futu will endeavour but cannot guarantee the accuracy and reliability of the above content, and will not be liable for any loss or damage arising from any inaccuracies or omissions.

(Responsible editor：Individual stock recommendation)

Last：Brother Wolf Kan stock market: 08.22 Today's stock market resumption and tomorrow's market trend forecast
Next：Guangdong Nanyue Bank Yunfu Branch: Welcome to the 20th National Congress, financial consultants enter the community